دورية أكاديمية
The rat with oxygen-induced retinopathy is myopic with low retinal dopamine.
| العنوان: | The rat with oxygen-induced retinopathy is myopic with low retinal dopamine. |
|---|---|
| المؤلفون: | Zhang N; Department of Ophthalmology, Boston Children's Hospital, Boston, Massachusetts., Favazza TL, Baglieri AM, Benador IY, Noonan ER, Fulton AB, Hansen RM, Iuvone PM, Akula JD |
| المصدر: | Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2013 Dec 19; Vol. 54 (13), pp. 8275-84. Date of Electronic Publication: 2013 Dec 19. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Association For Research In Vision And Ophthalmology (Arvo) Country of Publication: United States NLM ID: 7703701 Publication Model: Electronic Cited Medium: Internet ISSN: 1552-5783 (Electronic) Linking ISSN: 01460404 NLM ISO Abbreviation: Invest Ophthalmol Vis Sci Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Brookline Ma : Association For Research In Vision And Ophthalmology (Arvo) Original Publication: St. Louis, Mosby. |
| مواضيع طبية MeSH: | Disease Models, Animal*, Dopamine/*metabolism , Myopia/*etiology , Oxygen/*toxicity , Retinal Neurons/*metabolism , Retinopathy of Prematurity/*etiology, 3,4-Dihydroxyphenylacetic Acid/metabolism ; Animals ; Animals, Newborn ; Blotting, Western ; Chromatography, High Pressure Liquid ; Electroretinography ; Myopia/metabolism ; Myopia/physiopathology ; Rats ; Rats, Sprague-Dawley ; Retina/physiopathology ; Retinopathy of Prematurity/metabolism ; Retinopathy of Prematurity/physiopathology ; Retinoscopy |
| مستخلص: | Purpose: Dopamine (DA) is a neurotransmitter implicated both in modulating neural retinal signals and in eye growth. Therefore, it may participate in the pathogenesis of the most common clinical sequelae of retinopathy of prematurity (ROP), visual dysfunction and myopia. Paradoxically, in ROP myopia the eye is usually small. The eye of the rat with oxygen-induced retinopathy (OIR) is characterized by retinal dysfunction and short axial length. There have been several investigations of the early maturation of DA in rat retina, but little at older ages, and not in the OIR rat. Therefore, DA, retinal function, and refractive state were investigated in the OIR rat. Methods: In one set of rats, the development of dopaminergic (DAergic) networks was evaluated in retinal cross-sections from rats aged 14 to 120 days using antibodies against tyrosine hydroxylase (TH, the rate-limiting enzyme in the biosynthesis of DA). In another set of rats, retinoscopy was used to evaluate spherical equivalent (SE), electoretinography (ERG) was used to evaluate retinal function, and high-pressure liquid chromatography (HPLC) was used to evaluate retinal contents of DA, its precursor levodopamine (DOPA), and its primary metabolite 3,4-dihydroxyphenylacetic acid (DOPAC). Results: The normally rapid postnatal ramification of DAergic neurons was disrupted in OIR rats. Retinoscopy revealed that OIR rats were relatively myopic. In the same eyes, ERG confirmed retinal dysfunction in OIR. HPLC of those eyes' retinae confirmed low DA. Regression analysis indicated that DA metabolism (evaluated by the ratio of DOPAC to DA) was an important additional predictor of myopia beyond OIR. Conclusions: The OIR rat is the first known animal model of myopia in which the eye is smaller than normal. Dopamine may modulate, or fail to modulate, neural activity in the OIR eye, and thus contribute to this peculiar myopia. |
| References: | Brain Res Rev. 2007 Apr;54(1):181-8. (PMID: 17292477) Prog Brain Res. 2001;131:83-91. (PMID: 11420984) Eur J Neurosci. 2005 Apr;21(8):2199-208. (PMID: 15869516) Acta Ophthalmol Suppl. 1992;(204):10-5. (PMID: 1332382) Neuron. 2011 Oct 6;72(1):101-10. (PMID: 21982372) J Comp Neurol. 2000 Feb 28;418(1):33-40. (PMID: 10701754) J Comp Neurol. 1986 Jan 15;243(3):422-33. (PMID: 2869068) Nature. 1987 Jan 29-Feb 4;325(6103):437-9. (PMID: 2880299) Invest Ophthalmol Vis Sci. 2008 Feb;49(2):706-12. (PMID: 18235018) Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4351-9. (PMID: 17724227) Science. 1996 Apr 19;272(5260):419-21. (PMID: 8602533) Ophthalmology. 1998 Jul;105(7):1292-300. (PMID: 9663236) J Neurosci. 2012 Jul 4;32(27):9359-68. (PMID: 22764243) Doc Ophthalmol. 2010 Feb;120(1):41-50. (PMID: 19820974) Neuron. 1997 May;18(5):723-36. (PMID: 9182798) J Comp Neurol. 1980 May 15;191(2):27-36. (PMID: 7190979) Neuron. 2004 Aug 19;43(4):447-68. (PMID: 15312645) Invest Ophthalmol. 1971 Jun;10(6):438-52. (PMID: 4325307) Cell Mol Neurobiol. 1991 Oct;11(5):511-27. (PMID: 1720707) Doc Ophthalmol. 2010 Feb;120(1):25-39. (PMID: 19639355) Invest Ophthalmol Vis Sci. 2003 Mar;44(3):953-60. (PMID: 12601014) Vis Neurosci. 1993 May-Jun;10(3):447-53. (PMID: 8494798) Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8034-9. (PMID: 8755598) Invest Ophthalmol Vis Sci. 2008 Jan;49(1):453-7. (PMID: 18172125) Exp Eye Res. 2010 Nov;91(5):715-20. (PMID: 20801115) Vis Neurosci. 2003 Mar-Apr;20(2):211-20. (PMID: 12916741) Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5788-97. (PMID: 18055833) Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051) Nat Neurosci. 2001 Sep;4(9):877-86. (PMID: 11528418) Prog Retin Eye Res. 2009 Nov;28(6):452-82. (PMID: 19563909) Neuron. 1993 Apr;10(4):573-7. (PMID: 8476609) J Comp Neurol. 1990 Nov 15;301(3):461-89. (PMID: 1979792) Br J Ophthalmol. 2004 Jul;88(7):900-4. (PMID: 15205234) Vis Neurosci. 1989;2(5):465-71. (PMID: 2577263) Br J Pharmacol. 1999 Apr;126(8):1847-55. (PMID: 10372829) J Physiol. 1992 Apr;449:719-58. (PMID: 1326052) Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1674-7. (PMID: 2016144) Eur J Neurosci. 1997 May;9(5):1096-100. (PMID: 9182963) Eur J Neurosci. 2008 May;27(10):2691-700. (PMID: 18547251) Br J Ophthalmol. 2006 Apr;90(4):456-60. (PMID: 16547327) J Neurosci. 1993 Dec;13(12):5194-202. (PMID: 7902864) Vis Neurosci. 2000 Sep-Oct;17(5):769-80. (PMID: 11153656) Neurosci Lett. 1995 Sep 22;198(1):33-6. (PMID: 8570090) J Comp Neurol. 1990 Feb 15;292(3):480-94. (PMID: 1971284) Mol Vis. 2008;14:2499-508. (PMID: 19112532) Vis Neurosci. 1997 May-Jun;14(3):493-505. (PMID: 9194316) Ophthalmology. 1992 Mar;99(3):329-40. (PMID: 1565444) Pediatrics. 2002 Jan;109(1):12-8. (PMID: 11773536) Acta Ophthalmol Scand. 1996 Jun;74(3):301-5. (PMID: 8828732) Exp Eye Res. 2007 Jan;84(1):100-7. (PMID: 17094962) Brain Res. 2000 Nov 24;884(1--2):13-22. (PMID: 11082482) Neuroreport. 1994 Jan 12;5(4):401-4. (PMID: 7516196) Pediatr Res. 1994 Dec;36(6):724-31. (PMID: 7898981) J Neurosci. 2003 Apr 15;23(8):3145-53. (PMID: 12716922) Exp Eye Res. 1987 Mar;44(3):407-14. (PMID: 3595756) Doc Ophthalmol. 2001 Mar;102(2):115-30. (PMID: 11518455) Biochim Biophys Acta. 1993 Mar 1;1141(2-3):111-49. (PMID: 8382952) J Comp Neurol. 1989 Nov 1;289(1):99-110. (PMID: 2572614) Vision Res. 1978;18(7):793-800. (PMID: 676087) J Comp Neurol. 2008 Sep 10;510(2):158-74. (PMID: 18615559) J Neurosci. 2009 Nov 25;29(47):14903-11. (PMID: 19940186) Vis Neurosci. 1992 Feb;8(2):107-26. (PMID: 1558823) Doc Ophthalmol. 2004 Jan;108(1):17-40. (PMID: 15104164) Proc R Soc Lond B Biol Sci. 1980 Jul 17;208(1173):415-31. (PMID: 6158054) Exp Eye Res. 2010 Aug;91(2):153-61. (PMID: 20430026) Br J Ophthalmol. 1997 Jan;81(1):2-3. (PMID: 9135397) J Ophthalmol. 2012;2012:956705. (PMID: 22482037) J Comp Neurol. 2005 Jan 24;481(4):352-62. (PMID: 15593337) Vis Neurosci. 2004 Jul-Aug;21(4):533-43. (PMID: 15579219) Vis Neurosci. 2005 Jan-Feb;22(1):55-63. (PMID: 15842741) Invest Ophthalmol Vis Sci. 1994 Jun;35(7):2948-61. (PMID: 8206712) J Physiol. 1966 Aug;185(3):536-55. (PMID: 5918058) J Comp Physiol A. 1999 Apr;184(4):403-12. (PMID: 10377975) Neurosci Lett. 1981 Dec 23;27(3):255-9. (PMID: 6120490) Proc Natl Acad Sci U S A. 1989 Jan;86(2):704-6. (PMID: 2911600) Doc Ophthalmol. 2013 Aug;127(1):13-31. (PMID: 23775346) Doc Ophthalmol. 2009 Feb;118(1):55-61. (PMID: 18483822) Science. 1970 May 1;168(3931):605-6. (PMID: 5436596) J Comp Neurol. 1987 Nov 15;265(3):428-36. (PMID: 3693614) J Neurosci. 1987 Dec;7(12):4115-28. (PMID: 2891802) Doc Ophthalmol. 2010 Feb;120(1):3-12. (PMID: 19639356) Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5199-207. (PMID: 19036998) Ciba Found Symp. 1990;155:45-57; discussion 57-62. (PMID: 2088680) J Comp Neurol. 2010 Apr 15;518(8):1220-31. (PMID: 20148440) Invest Ophthalmol Vis Sci. 2013 Sep 05;54(9):6018-24. (PMID: 23920368) Am J Ophthalmol. 2008 Jun;145(6):1090-4. (PMID: 18374298) |
| معلومات مُعتمدة: | R01 EY004864 United States EY NEI NIH HHS; RC1 EY020308 United States EY NEI NIH HHS; R01EY004864 United States EY NEI NIH HHS; P30 EY006360 United States EY NEI NIH HHS; P30EY006360 United States EY NEI NIH HHS; RC1EY020308 United States EY NEI NIH HHS |
| فهرسة مساهمة: | Keywords: development; dopamine; myopia; ocular; rat; retinopathy of prematurity |
| المشرفين على المادة: | 102-32-9 (3,4-Dihydroxyphenylacetic Acid) S88TT14065 (Oxygen) VTD58H1Z2X (Dopamine) |
| تواريخ الأحداث: | Date Created: 20131031 Date Completed: 20140212 Latest Revision: 20220310 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3869423 |
| DOI: | 10.1167/iovs.13-12544 |
| PMID: | 24168993 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1552-5783 |
|---|---|
| DOI: | 10.1167/iovs.13-12544 |